DNA-Guided chemo aims to stop colon cancer return
NCT ID NCT05062889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether using a blood test for circulating tumor DNA (ctDNA) can help doctors decide if patients with stage II or III colon cancer need stronger chemotherapy after surgery. The trial compares standard chemo with a more intense regimen (FOLFOXIRI) and an additional drug (Trifluridine/Tipiracil) for those still at high risk. A separate group with HER2-positive cancer will receive targeted therapy. The goal is to see if these approaches can make ctDNA undetectable, which may lower the chance of cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (FOLFOXIRI, FOLFOX, Trifluridine/Tipiracil, Trastuzumab, Tucatinib)
- What this could lead to
- If successful, this could show that using ctDNA to guide more aggressive chemotherapy reduces the chance of colon cancer returning after surgery.
- What could go wrong
- This is a phase 2 trial that is currently suspended, so results are far from certain. The intensified chemo may cause more side effects and may not improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O.U Careggi
Florence, 50134, Italy
-
A.O.U. di Ferrara Arcispedale Sant'Anna
Ferrara, 44100, Italy
-
AOU Cagliari PO Policlinico Universitario Duilio Casula Presidio Policlinico Universitario "Duilio Casula"
Cagliari, 09042, Italy
-
AUSL Romagna
Ravenna, 48121, Italy
-
Azienda Ospedaliera Cardinale Giovanni Panico
Tricase, Lecce, 73039, Italy
-
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, 28100, Italy
-
Azienda Sanitaria Universitaria Friuli Centrale
Udine, 33100, Italy
-
Azienda USL IRCCS di Reggio Emilia (centro principale Reggio Emilia e centro satellite Guastalla).
Reggio Emilia, 42123, Italy
-
Azienda USL Toscana Nord Ovest di Livorno
Livorno, 57124, Italy
-
Azienda USL di Piacenza
Piacenza, 29121, Italy
-
E.O. Ospedali Galliera di Genova
Genova, 16128, Italy
-
Fondazione Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, 71013, Italy
-
Fondazione IRCCS INT - Milano
Milan, 20133, Italy
-
Fondazione POLIAMBULANZA ISTITUTO OSPEDALIERO
Brescia, 25124, Italy
-
IRCCS di Candiolo
Torino, 10060, Italy
-
Istituto Oncologico Veneto IOV - IRCCS
Padua, 35128, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, 47014, Italy
-
Istituto per la ricerca sui tumori Regina Elena
Roma, 00144, Italy
-
Nuovo Ospedale di Prato
Prato, 59100, Italy
-
Ospedale Campostaggia Poggiponsi
Siena, 53100, Italy
-
Ospedale Fatebenefratelli Isola Tiberina
Roma, 00186, Italy
-
Ospedale Misericordia di Grosseto
Grosseto, 58100, Italy
-
Ospedale San Donato di Arezzo
Arezzo, 52100, Italy
-
Ospedale San Luca di Lucca
Lucca, 55100, Italy
-
Ospedale San Raffaele
Milan, 20132, Italy
-
Policlinico Fondazione Agostino Gemelli
Roma, 00168, Italy
-
Policlinico Tor Vergata Roma
Roma, 00133, Italy
-
Spedali Civili di Brescia
Brescia, 25123, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test tell who needs more cancer treatment?
- Can adding cetuximab to chemotherapy prevent colon cancer return?
- Can an arthritis drug boost chemo for colon cancer?
- Blood test may spare some colon cancer patients from chemo
- New genetic test may predict colon cancer return
- Could probiotics tame Chemo's worst symptoms?